MarketCap
Facebook
X
Telegram
Personalis Revenue | PSNL
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Personalis
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 69.6 M | 84.6 M | 73.5 M | 65 M | 85.5 M | 78.6 M | 65.2 M | 37.8 M | 9.39 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 85.5 M | 9.39 M | 63.3 M |
Quarterly Revenue Personalis
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.4 M | 15.5 M | 14.5 M | 17.2 M | 20.6 M | - | 25.7 M | 22.6 M | 19.5 M | - | 18.2 M | 16.7 M | 18.9 M | - | 14.9 M | 18.2 M | 15.2 M | - | 22.3 M | 21.7 M | 20.9 M | - | 19.8 M | 19.5 M | 19.2 M | 18.2 M | 17.2 M | 15.8 M | 14.1 M | 13.2 M | 11.7 M | 8.8 M | 4.16 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 25.7 M | 4.16 M | 17.4 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
CareDx, Inc
CDNA
|
380 M | $ 54.31 | 0.32 % | $ 2.89 B |  USA |
 |
Co-Diagnostics
CODX
|
622 K | $ 1.1 | 1.85 % | $ 1.46 M | USA |
 |
Castle Biosciences
CSTL
|
344 M | $ 34.88 | 0.09 % | $ 1.01 B | USA |
 |
Danaher Corporation
DHR
|
24.6 B | $ 221.56 | 0.21 % | $ 158 B | USA |
 |
DexCom
DXCM
|
4.66 B | $ 87.73 | 0.21 % | $ 34.2 B | USA |
 |
Fulgent Genetics
FLGT
|
323 M | $ 21.27 | 0.51 % | $ 655 M | USA |
 |
Guardant Health
GH
|
982 M | $ 176.31 | 0.27 % | $ 22.1 B | USA |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
8.25 B | $ 163.9 | 0.2 % | $ 12.9 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
4.3 B | $ 522.02 | 0.1 % | $ 42 B | USA |
 |
IQVIA Holdings
IQV
|
16.3 B | $ 267.86 | 0.41 % | $ 46 B | USA |
 |
Anixa Biosciences
ANIX
|
210 K | $ 2.75 | 3.33 % | $ 89.2 K | USA |
 |
Laboratory Corporation of America Holdings
LH
|
14 B | $ 303.98 | 0.09 % | $ 25.3 B | USA |
 |
Lantheus Holdings
LNTH
|
1.54 B | $ 99.97 | 0.01 % | $ 6.75 B | USA |
 |
Medpace Holdings
MEDP
|
2.53 B | $ 617.15 | 0.23 % | $ 17.8 B | USA |
 |
Mettler-Toledo International
MTD
|
4.03 B | $ 1 492.34 | 0.11 % | $ 30.8 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
824 M | $ 4.01 | 0.62 % | $ 371 M | USA |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 6.5 | 4.33 % | $ 5.12 M | USA |
 |
NeoGenomics
NEO
|
727 M | $ 18.36 | 0.03 % | $ 2.35 B | USA |
 |
Neogen Corporation
NEOG
|
870 M | $ 13.57 | 2.72 % | $ 2.95 B | USA |
 |
Natera
NTRA
|
2.31 B | $ 390.79 | 0.41 % | $ 53.4 B | USA |
 |
Biomerica
BMRA
|
4.45 M | $ 2.61 | 0.36 % | $ 7.61 M | USA |
 |
OPKO Health
OPK
|
148 M | $ 1.7 | 0.29 % | $ 1.28 B | USA |
 |
RadNet
RDNT
|
2.04 B | $ 73.21 | 0.11 % | $ 5.5 B | USA |
 |
Sotera Health Company
SHC
|
1.16 B | $ 18.29 | 0.45 % | $ 5.19 B | USA |
 |
Neuronetics
STIM
|
149 M | $ 2.88 | 0.21 % | $ 190 M | USA |
 |
Trinity Biotech plc
TRIB
|
61.6 M | $ 7.01 | 0.68 % | $ 2.52 B | Irlanda |
 |
Twist Bioscience Corporation
TWST
|
377 M | $ 158.47 | 0.93 % | $ 9.48 B | USA |
 |
Biodesix
BDSX
|
88.5 M | $ 29.29 | 4.05 % | $ 221 M | USA |
 |
VolitionRx Limited
VNRX
|
1.73 M | $ 0.25 | 2.99 % | $ 31.4 M |  Singapore |
 |
Waters Corporation
WAT
|
932 M | $ 420.57 | 0.52 % | $ 25 B | USA |
 |
Exagen
XGN
|
66.6 M | $ 8.55 | 1.39 % | $ 184 M | USA |
 |
Syneos Health
SYNH
|
5.39 B | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
2.29 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
Psychemedics Corporation
PMD
|
19.7 M | - | -1.84 % | $ 15.3 M | USA |
 |
Quotient Limited
QTNT
|
38.5 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
T2 Biosystems
TTOO
|
7.19 M | - | -39.35 % | $ 313 K | USA |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
Meridian Bioscience
VIVO
|
333 M | - | - | $ 1.49 B | USA |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
11.7 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
28.5 M | $ 1.7 | 0.55 % | $ 9.26 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
540 M | $ 15.08 | 11.68 % | $ 162 M |  China |
 |
Bioventus
BVS
|
568 M | $ 13.61 | 2.55 % | $ 907 M | USA |
 |
Brainsway Ltd.
BWAY
|
41 M | $ 13.45 | 0.88 % | $ 457 M | Israel |